PBM Audits and Pharmacy Clawbacks: The Audit Kept Finding the Error

PBM audit clawback fraud can leave a government plan paying for medicine never delivered or drug costs reported falsely. The pharmacy bill, the money taken back and the report sent to the payer can tell different stories about the same prescription. If you work in pharmacy operations, auditing or reconciliation, you may know where those stories part company. We follow the money and the decisions behind the report with you.

What a PBM Audit Tests

A pharmacy audit compares the billed prescription with the order, the medicine supplied and the payment. A sponsor’s review of its PBM adds another comparison: what the sponsor funded, what the pharmacy received and what the contract required the PBM to credit back.

Inventory is one part of that comparison. Supplier invoices, shipment records and purchasing ledgers show what the pharmacy acquired. The prescription supplies the directions and authorized quantity. Dispensing and delivery records show what went to the patient. The original claim, rejection, override, reversal and rebill history show what the processor was told.

Days supply matters because it connects the quantity dispensed to when the patient should need more. The CVS insulin case below shows how a software value can keep generating the same problem after an audit has identified it.

On the PBM side, the network agreement and final pharmacy remittance show reimbursement and recoupments. The sponsor agreement, invoice and year-end reconciliation show funding, fees and contractual pricing and rebate commitments. Manufacturer receipts may sit with a rebate intermediary.

Does a Paid Pharmacy Claim Prove Delivery?

A paid pharmacy claim shows a billing result. Pickup and delivery records show whether the patient received the medicine. New York’s NYRx pharmacy policy expressly distinguishes submitting a claim from furnishing the prescription.

The government’s allegations in the Walgreens settlement agreement show why that distinction matters inside a pharmacy system. Intercom Plus allegedly moved unsold or undeleted orders after 29 days into a central Unaccounted-For Status, outside local work queues. The government alleged that no separate back-end process resolved those orders.

A cleared local queue could therefore leave a paid claim unresolved elsewhere. The order disappears from the employee’s screen while the payer still carries the bill.

For Medicare Part D, the sponsor’s Prescription Drug Event record also needs to reflect the correction. We connect that federal report to the claim reversal and the payer’s refund.

Are Clawbacks and DIR the Same Thing?

An audit clawback recovers a claimed overpayment. Medicare Part D direct and indirect remuneration, usually called DIR, accounts for concessions that reduce plan drug costs. The reason for the adjustment determines its reporting treatment.

The Centers for Medicare & Medicaid Services’ post-point-of-sale guidance, issued in 2013, calls for recovery of the cost and deletion of the Prescription Drug Event record for an undispensed drug or duplicate claim, rather than DIR reporting. For a drug dispensed in error that qualifies as a Part D drug, the guidance instead calls for recovery and a zero-dollar event record, with corrected benefit totals.

That difference preserves what happened. Medicine never furnished and medicine furnished in error leave different federal records, even when both involve money coming back.

Pharmacy price concessions have their own accounting. The rule establishing the 2024 negotiated-price change moved pharmacy concessions into the lowest possible reimbursement used at the counter. Plans still had to report the difference between that price and the pharmacy’s final reimbursement. An audit recovery, a price concession, a patient’s copay and an administrative fee each need their own description before anyone can say where the money belongs.

When Audit Chargebacks Keep Finding the Same Error

Repeated chargebacks can show that management knew the billing problem. In the government’s insulin case against CVS Pharmacy, the complaint alleged that dispensing software calculated refill dates using frequently inaccurate days-supply data. Staff then refilled prescriptions prematurely, supplying more insulin than patients needed under their prescriptions.

The government alleged that PBM audits repeatedly identified invalid supply data, early refills and excess quantities. PBMs charged the money back. According to the complaint, management knew insulin pens were among the products most frequently charged back for premature refills, yet failed to address the problem.

The audits caught it. The refill software kept doing it. We would follow the chargebacks to the people who left that process running.

CVS agreed to a $37.76 million court-approved settlement in December 2025 and made factual admissions. The government joined cases brought by whistleblowers. The resolved allegations concerned premature refills, excess pens and understated supply billed to federal healthcare programs. The release puts the refill calculation at the center: it had to use the actual supply dispensed, even when a PBM permitted a different value in the claim field.

The Patient’s Copay Has Its Own Payment Trail

A patient receipt, a government payment and a manufacturer’s coupon payment can describe different parts of the same prescription. The whistleblower complaint against Kmart alleged that the pharmacy obtained an additional payment through manufacturer coupons that reduced government-program patients’ copays:

The complaint also alleged that Kmart submitted third-party claims without informing Medicare or Medicaid. Kmart paid $1.4 million in 2015 to resolve allegations involving coupons and gasoline discounts used as inducements.

For a patient copay clawback concern, we compare the patient receipt and adjudicated copay with the final pharmacy remittance. An audit recovery from the pharmacy and a credit to the plan require their own payment records. The Kmart parallel shows why a third-party payment also belongs in that comparison.

The PBM’s Report Can Change What the Government Pays

The reporting problem can sit beyond the individual pharmacy claim, in a reconciliation of contractual pricing commitments, a rebate classification or an omitted credit. These cases and audits show why the final accounting belongs beside the original transaction.

Caremark’s Offsets Between Part D and Commercial Business

A federal court found that higher Part D pharmacy payments reduced Caremark’s obligations under its commercial pharmacy reconciliations. Those offsets were reportable price concessions even though no separate refund check went back to the Part D sponsor, according to the court’s findings. A Medicare actuary brought the whistleblower case.

The economic benefit appeared in another part of the business. A review confined to the prescription claim or a search for a refund check would miss the offset. The contractual commitments for overall generic-drug reimbursement, reconciliation workbooks and sponsor reports supply the connection.

The resulting judgment was $289,873,500 against three Caremark operating companies jointly. The court rejected liability for parent CVS Health.

Elixir’s Alleged Rebate Reclassification

The government alleged that Elixir excluded retained manufacturer rebates from Part D reports by classifying them as service fees. Its settlement agreement describes the formula as 20% of estimated rebates from 2014 through 2019, then 5.5% of wholesale acquisition cost in 2020.

The apparent drop in the percentage hides a change in what was being measured. One formula used estimated rebates. The other used a drug-price benchmark. An insider comparing the reports needs the underlying receipts and the calculation, alongside the label assigned to the payment. Rite Aid and Elixir Insurance Company agreed to a $101 million fixed settlement obligation, with a separate $20 million claim in the bankruptcy.

Compass Rose’s Audit Followed the Money to Ascent

The Office of Personnel Management’s inspector general examined Express Scripts-administered pharmacy operations for the Compass Rose federal employee health plan. Its November 2024 audit reported $18,443,118 in findings, including lost investment income, across retail discounts, transaction fees, inventory discounts and manufacturer rebates.

The inspector general reported that rebate intermediary Ascent collected $70,382,646, but $60,343,427 passed through. After offsetting payments made under the contractual rebate commitment, the carrier’s response confirmed a wire returning $9,524,945 in principal to the Federal Employees Health Benefits Program.

Cigna disputed several findings and framed the rebate payment as resolving a contract interpretation dispute. Whatever the framing, its response confirmed money going back to the federal employee program.

The audit did not project its sampled findings across all claims. A demand based on a sample needs to be read alongside the claims examined and the final credit.

What Does 100% Pass-Through Cover?

A pass-through promise covers the receipts its contract defines. Minnesota’s Caremark agreement effective in 2021 promises all defined rebates while excluding specified mail and specialty purchasing discounts and specialty service revenue.

For an insider, the useful questions are which entity received the money, which category it entered and what reached the client after reconciliation of the contractual rebate commitment. A fee classification can decide whether a payment appears in the contract’s rebate total.

Part D adds a separate reporting question. Its drug-cost rules reach qualifying concessions retained by an intermediary. The sponsor’s contractual right to receive the money and its duty to report the concession require separate comparisons. That is why we follow both the contract payment and the federal report.

What the Records Need to Connect

The strongest account follows the alleged error from the prescription through the audit to the final payer report. It shows who recovered the money, who was entitled to it and what the sponsor reported.

An initial finding may change after an appeal or response. We work through the disputed transaction, any sampling calculation and the final finding with you, then follow the recovery to the client’s credit.

Your role may give you direct knowledge of the software setting, repeated finding, fee classification or instruction that produced the report. We connect that knowledge to the payment evidence with you. Questions about which records you can lawfully describe belong in that conversation with our whistleblower experts.

PBM Audit Clawback Fraud and a Whistleblower Case

A PBM fraud whistleblower case identifies who made the false claim or report, what they knew and how it affected government payment. The pharmacy’s dispensing records, the PBM’s reconciliations and the sponsor’s submissions can each supply part of that account.

A qui tam whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We assess the claim, the reporting decision and the payment together to build your health care fraud case.

When You Can See Where the Recovery Went

If you work in a pharmacy, PBM, plan or audit team and know why a recovery and a payer report tell different stories, speak with our whistleblower experts about the fraud you see. We work beside you to build your strongest PBM whistleblower case around the claims, credits and decisions you understand, and bring in PBM fraud whistleblower lawyers with the right contract and reporting experience. We bring the expertise and partnership to pursue it with you.